Eco Animal Health has announced the divestiture of certain non-core product lines to its long-time distribution partner in South Africa. The transaction, worth £0.49 million, will allow Eco Animal Health to sharpen its focus on disease treatment and prevention in pigs and poultry, potentially reshaping the veterinary pharmaceuticals landscape.
The AIM-listed company has offloaded ECOmectin licences, targeting anti-parasitic treatments for sheep and cattle in southern Africa. This move aligns with its strategic pivot towards core sectors of swine and poultry medicine. The divested assets were deemed non-vital, having contributed no royalties for the year ending 31 March 2024. For over two decades, Eco’s South African partner has been responsible for the licenced manufacturing and sales of these products, marking a continuation rather than a halt in their availability. The proceeds are earmarked for reinvesting in the company’s robust R&D pipeline, targeting the development of new vaccines and preventative treatments. Additionally, subject to shareholder approval, funds may support a share buyback initiative, addressing employee share incentives.
By selling these non-core assets, Eco Animal Health is streamlining its operations to enhance growth within its primary sectors. According to CEO David Hallas, this strategic realignment supports the company’s commitment to innovation and sustainable development in veterinary medicine. The share market’s positive response suggests confidence in Eco’s forward-looking strategy.
